Truscreen Shareholder Meeting Date and Director Nominations

NZX/ASX Announcement

17 July 2025



NZX Limited
Wellington


TruScreen Group Limited – Annual Shareholders’ Meeting and Director Nomination dates
Truscreen Group Limited (NZX/ASX:TRU) (Truscreen or Company) advises that:

• The Annual Shareholders’ Meeting will be held on Thursday 11 September 2025

• The director nominations period is now open. The closing date for nominations will be Friday 25
July 2025. Director nominations should be sent to:


Guy Robertson
Chief Financial Officer
Truscreen Group Limited
guyrobertson@truscreen.com




Guy Robertson
Chief Financial Officer

About TruScreen:

TruScreen Group Limited (NZX/ASX: TRU) is a medical device company that has developed and manufactures
an AI-enabled device for detecting abnormalities in the cervical tissue in real-time via measurements of the low
level of optical and electrical stimuli.
TruScreen’s cervical screening technology enables cervical screening, negating sampling and processing of
biological tissues, failed samples, missed follow-up, discomfort, and the need for costly, specialised personnel
and supporting laboratory infrastructure.
The TruScreen device, TruScreen Ultra
®
, is registered as a primary screening device for cervical cancer
screening.
The device is CE Marked/EC certified, ISO 13485 compliant and is registered for clinical use with the TGA
(Australia), MHRA (UK), NMPA (China), SFDA (Saudi Arabia), Roszdravnadzor (Russia), and COFEPRIS
(Mexico). It has Ministry of Health approval for use in Vietnam, Israel, Ukraine, and the Philippines, among
others and has distributors in 29 countries. In 2021, TruScreen established a manufacturing facility in China for
devices marketed and sold in China.
TruScreen technology has been recognised in CSCCP’s (Chinese Society for Colposcopy and Cervical
Pathology) China Cervical Cancer Screening Management Guideline.
TruScreen has been recognised in a China Blue Paper “Cervical Cancer Three Stage Standardized Prevent
and Treatment” published on 28 April 2023.
In Dec 2023 TruScreen technology was added to the Vietnam Ministry of Health approved National Technical
List, for use in Vietnam’s public and private healthcare sectors
In financial year 2024 alone, over 200,000* examinations have been performed with TruScreen device. To date,
over 200 devices have been installed and used in China, Vietnam, Mexico, Zimbabwe, Russia, and Saudi
Arabia. TruScreen’s vision is “A world without the cervical cancer”
©
.
To learn more, please visit: www.truscreen.com/.
*Based on Single Use Sensor sales.